Guillaume Courbon: New Publication on Erythroid-Produced FGF23 and Its Role in Anemia
Guillaume Courbon, Assitant Professor at National Institute of Health and Medical Research (INSERM), shared a post on LinkedIn:
“Accepted earlier this year, our work is featured this month’s issue of Blood:
‘Erythroid-produced intact FGF23 is a paracrine inhibitor of erythropoiesis‘
FGF23 is best known as a hormone produced by bone cells to regulate phosphate homeostasis. But our work reveals another, rather unexpected, side of FGF23 biology.
It’s been known for quite a while that intact FGF23 (iFGF23) production and cleavage move alongside iron metabolism, and iron deficiency is a trigger to excess iFGF23 in patients not able to get rid of it.
We show that, under iron deficiency, erythroid cells produce iFGF23, which acts locally in the bone marrow to inhibit erythropoiesis.
Using genetic models, we found that:
- erythroid-derived iFGF23 contributes directly to anemia in iron deficiency
- production of iFGF23 in erythroid cells aggravates anemia
- iFGF23 directly impairs erythroid progenitor differentiation through FGFR1, associated with mitochondrial dysfunction
- and, importantly, targeting deletion of Fgf23 in erythroid alleviates anemia in a model of progressive chronic kidney disease
These findings suggest that FGF23 has functions extending well beyond phosphate regulation, and highlight a potential link between iron metabolism, erythropoiesis, FGF23 and anemia.
This work was led by Dr Valentin David from Northwestern University – The Feinberg School of Medicine and was made possible thanks to all co-authors, including Drs Jane Joy Thomas, Aline Martin, Peng Ji, Tamara Isakova and the entire team involved in this project.
I am happy to see this work ‘officially’ published, excited about the questions it opens for the field, and looking forward to our continued collaboration in my current position.”
Title 1: Erythroid-produced intact FGF23 is a paracrine inhibitor of erythropoiesis
Authors: Guillaume Courbon, Jane Joy Thomas, Eduardo J. Duque, Dominik Kentrup, Jadeah Jeannine Spindler, William Semanchek, Emily Tracey, Douglas E. Vaughan, Wenhan Chang, John W. M. Creemers, Peng Ji, Tamara Isakova, Aline Martin, Valentin David
Read the Full Article on Blood
Title 2: FGF23 factories in iron deficiency and anemia of CKD
Authors: Myles Wolf
Read the Full Article on Blood
Title 3: Role of erythroid fibroblast growth factor 23 in regulating erythropoiesis
Authors: Tilman B. Drüeke, Ziad A. Massy
Read the Full Article on Kidney International
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 16, 2026, 17:32Shruthi Narayan: STORM-PE and STRIKE-PE Studies Advance Understanding of Recovery After Pulmonary Embolism
-
Oct 16, 2026, 17:22Wolfgang Miesbach։ What a Near-Perfect FISH Score Fails to See
-
Oct 16, 2026, 17:06Troels Wienecke: Connecting Myeloproliferative Disease and Ischemic Stroke
-
Oct 16, 2026, 17:03Only 5 Days Left to Submit Your Research for EAHAD 2027
-
Oct 16, 2026, 16:48Abdul Rahman: Reticulocyte Count and Bone Marrow Activity
-
Oct 16, 2026, 16:44DOAC Adherence in Stroke Patients With Atrial Fibrillation – International Journal of Stroke
-
Oct 16, 2026, 16:22Shannon Farmer: Driving Patient Blood Management Forward in Australia and New Zealand
-
Oct 16, 2026, 16:01Obi Light Ogbonnia: The Greatest Reward Is Changing Lives, Not Winning Awards
-
Oct 16, 2026, 15:18Carmine Liberatore: Limited Accuracy of VTE Risk Scores in Multiple Myeloma